middle.news
Neurizon Advances NUZ-001 ALS Therapy Amid $16.6M Loss: What’s Next?
11:28pm on Friday 29th of August, 2025 AEST
•
Biotechnology
Read Story
Neurizon Advances NUZ-001 ALS Therapy Amid $16.6M Loss: What’s Next?
11:28pm on Friday 29th of August, 2025 AEST
Key Points
Net loss doubles to $16.6 million in FY2025
NUZ-001 shows promising Phase 1 and extension study results
Orphan Drug Designation granted in US and Europe
Exclusive global license agreement signed with Elanco Animal Health
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEURIZON THERAPEUTICS (ASX:NUZ)
OPEN ARTICLE